Table 1.
Participant | Age (years) | History of atopya | Smoking status | Sex | Height (cm) | Weight (kg) | BMI (kg/m2) | Asthma duration (years) | FEV1 at inclusion (FEV1 % predicted) | PD20 methacholine at baseline (μg) | Percent eosinophils in sputum at baselineb |
---|---|---|---|---|---|---|---|---|---|---|---|
1c | 26 | Yes | N | F | 164 | 57 | 21 | 8 | 3.23 (110) | 1,600 | NA |
2 | 29 | No | E | M | 185 | 90 | 27 | 11 | 4.13 (89) | 1,490 | 14.73 |
3 | 29 | No | N | M | 182 | 87 | 27 | 10 | 4.43 (99) | 690 | 11.88 |
4 | 31 | No | N | M | 161 | 84 | 33 | 8 | 2.87 (81) | 3,200 | 6.79 |
5 | 28 | No | N | M | 174 | 74 | 25 | 4 | 3.69 (88) | 1,550 | 1.68 |
6 | 27 | No | N | M | 180 | 88 | 28 | 21 | 3.57 (80) | 1,220 | 0.93 |
7 | 24 | No | N | M | 178 | 70 | 22 | 8 | 3.88 (87) | 1,070 | 4.25 |
8 | 30 | No | N | F | 159 | 56 | 22 | 20 | 3.03 (103) | 500 | 2.68 |
9 | 29 | Yes | N | M | 168 | 72 | 26 | 22 | 3.89 (100) | 3,200 | 1.88 |
10c | 28 | Yes | N | M | 186 | 92 | 27 | 2 | 4.49 (96) | 800 | ANR |
11 | 20 | Yes | N | F | 158 | 49 | 20 | 9 | 2.29 (76) | 930 | 0.26 |
12 | 69 | No | N | M | 178 | 90 | 29 | 5 | 2.49 (78) | 3,200 | 17.72 |
13 | 30 | No | N | F | 163 | 55 | 21 | 20 | 2.68 (87) | 1,950 | 32.08 |
14 | 32 | Yes | N | M | 179 | 82 | 26 | 24 | 4.12 (92) | 340 | 2.51 |
15 | 24 | No | N | F | 171 | 60 | 21 | 14 | 3.41 (97) | 310 | 5.12 |
16 | 28 | No | N | M | 174 | 62 | 21 | 16 | 3.82 (91) | 2,100 | 20.58 |
17 | 32 | No | N | M | 176 | 115 | 38 | 21 | 4.16 (100) | 2,170 | 2.99 |
18c | 30 | Yes | N | M | 169 | 89 | 32 | 21 | 3.75 (95) | 190 | NA |
19 | 30 | No | N | M | 174 | 115 | 39 | 23 | 3.16 (76) | 210 | 1.55 |
Abbreviations: ANR: available but not relevant because participant 10 did not complete the three series of exposure; E, ex-smoker; N, never-smoker; NA: not available. aPersonal history of atopic dermatitis and/or atopic familial history. bPercent eosinophils at baseline (10–30 days before first exposure). cParticipants excluded from the analysis: participants 1 and 18 did not produce adequate sputum specimens for cell analysis at baseline (squamous cells > 20%); participant 10 did not complete the three series of exposure. |